Monitoring photodynamic therapy of head and neck malignancies with optical spectroscopies

Table 1 Photodynamic therapy-induced changes in photodynamic therapy-related parameters for two patients

	Lesion type	STAT3	ΔBFI	ΔBVf	ΔStO2	ΔcHPPH
P1	CIS	35%	83.4%	23%	+15.2%	51.8%
P2	Dysplasia	0.3%	59.2%	7.5%	-17%	38.6%

Changes in BFI was significant for both patients while changes in cHPPH were only significant for patient-1. Adapted from the reference[74] with the permission. Δ represents changes in parameters. STAT3: Signal transducer and activator of transcription 3; cHPPH: photosensitizer concentration; BFI: Blood flow index; BVf: Blood volume fraction; StO2: Saturation; P1: Patient-1; P2: Patient-2; CIS: Carcinoma in situ.

Table 2 Pretreatment contrasts in photodynamic therapy-related parameters between two patients (mean ± SE)

	Lesion type	BFI (a.u.)	BVf (%)	StO2 (%)	cHPPH (μmol/L)
P1	CIS	6.7 ± 2.8	2.5 ± 0.7	74 ± 2	0.34 ± 0.02
P2	Dysplasia	1.8 ± 0.5	1.3 ± 0.2	64 ± 3	0.10 ± 0.03

All parameters except blood volume fraction showed a significant difference between two patients. Adapted from the reference[74] with the permission. cHPPH: photosensitizer concentration; BFI: Blood flow index; BVf: Blood volume fraction; StO2: Saturation; P1: Patient-1; P2: Patient-2; CIS: Carcinoma in situ.